Peng Xiang-Hong, Qian Ximei, Mao Hui, Wang Andrew Y, Chen Zhuo Georgia, Nie Shuming, Shin Dong M
Department of Medical Oncology/Hematology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Int J Nanomedicine. 2008;3(3):311-21. doi: 10.2147/ijn.s2824.
Magnetic iron oxide (IO) nanoparticles with a long blood retention time, biodegradability and low toxicity have emerged as one of the primary nanomaterials for biomedical applications in vitro and in vivo. IO nanoparticles have a large surface area and can be engineered to provide a large number of functional groups for cross-linking to tumor-targeting ligands such as monoclonal antibodies, peptides, or small molecules for diagnostic imaging or delivery of therapeutic agents. IO nanoparticles possess unique paramagnetic properties, which generate significant susceptibility effects resulting in strong T2 and T*2 contrast, as well as T1 effects at very low concentrations for magnetic resonance imaging (MRI), which is widely used for clinical oncology imaging. We review recent advances in the development of targeted IO nanoparticles for tumor imaging and therapy.
具有长血液滞留时间、生物可降解性和低毒性的磁性氧化铁(IO)纳米颗粒已成为体外和体内生物医学应用的主要纳米材料之一。IO纳米颗粒具有大的表面积,并且可以进行工程设计以提供大量官能团,用于与肿瘤靶向配体(如单克隆抗体、肽或小分子)交联,以进行诊断成像或治疗剂递送。IO纳米颗粒具有独特的顺磁性特性,可产生显著的磁化率效应,从而在磁共振成像(MRI)中产生强烈的T2和T*2对比度,以及在非常低的浓度下产生T1效应,MRI广泛用于临床肿瘤学成像。我们综述了用于肿瘤成像和治疗的靶向IO纳米颗粒开发的最新进展。